Back to School: How biopharma can reboot drug development. Access exclusive analysis here

S-59: Phase III study update

Cerus Corp. (CERS), Concord, Calif.
Product: S-59
Business:

Read the full 83 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE